Guilherme Nader-Marta, MD, and Erica L. Mayer, MD, MPH, discusses innovative treatments for HR-positive, HER2-negative metastatic breast cancer.
Vol.26/No.11
Emerging technologies and process reconsiderations may alleviate time and resource stressors oncology teams face when appealing patient insurance denials.
ENPP3 offers a potentially attractive treatment target in patients with clear cell RCC.
Although clinical trials are considered a “gold standard” in identifying the efficacy of treatments, real-world data help address unmet needs in colorectal cancer.
Ramez N. Eskander, MD, discusses prior data supporting the ongoing investigation of sacituzumab govitecan as monotherapy in endometrial cancer.
Hans Lee, MD; and Nisha Joseph, MD, discuss the FDA approval of linvoseltamab for the treatment of patients with relapsed/refractory multiple myeloma.
Naoto T. Ueno, MD, PhD, FACP, discusses treatment sequencing considerations in HER2+ advanced or metastatic breast cancer.
In an OncLive Peer Exchange, a panel of lung cancer experts discussed updated data in EGFR-mutated NSCLC from WCLC 2025.
Advertisement
Advertisement
Trending on OncLive
1
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
2
Nonresponse to Bridging Therapy and Peak ALC After Cilta-Cel Are Associated With Neurotoxicity, NRM in Myeloma
3
FDA Underscores Risks Associated With DPD Deficiency and Capecitabine/5-FU Use in Cancer Care
4
FDA Updates Axi-Cel Label to Remove Limitation of Use in R/R PCNSL
5